Staphylococcus Aureus Bacteremia Clinical Trials

7 recruiting

Frequently Asked Questions

Common questions about Staphylococcus Aureus Bacteremia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 17 of 7 trials

Recruiting
Phase 4

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia

Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+3 more
McGill University Health Centre/Research Institute of the McGill University Health Centre300 enrolled1 locationNCT06650501
Recruiting
Phase 4

Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia

Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+2 more
Todd C. Lee MD MPH FIDSA300 enrolled14 locationsNCT06637332
Recruiting
Phase 2

Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia

Staphylococcus Aureus BacteremiaStaphylococcus Aureus EndocarditisStaphylococcus Aureus Septicemia+1 more
Todd C. Lee MD MPH FIDSA60 enrolled5 locationsNCT04886284
Recruiting
Phase 4

Staphylococcus Aureus Network Adaptive Platform Trial

Staphylococcus Aureus Bacteremia
University of Melbourne8,000 enrolled151 locationsNCT05137119
Recruiting
Not Applicable

Evaluating Simplified Layered Consent for Clinical Trials

Staphylococcus Aureus Bacteremia
Sunnybrook Health Sciences Centre346 enrolled6 locationsNCT06168474
Recruiting

Identification and Validation of Clinical Phenotypes in Staphylococcus Aureus Bacteremia and Their Association With Mortality and Development of Complicated Bacteremia

Staphylococcus Aureus Bacteremia
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla1,000 enrolled1 locationNCT06574399
Recruiting
Phase 3

Early Intravenous to Oral Antibiotic Switch in Uncomplicated Staphylococcus Aureus Bacteraemia

Staphylococcus Aureus Bacteremia
Clinical Research Centre, Malaysia290 enrolled12 locationsNCT06336824